Form 8-K - Current report:
SEC Accession No. 0001193125-25-129531
Filing Date
2025-05-28
Accepted
2025-05-28 16:42:58
Documents
17
Period of Report
2025-05-23
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d911818d8k.htm   iXBRL 8-K 37581
2 EX-4.1 d911818dex41.htm EX-4.1 69246
3 EX-10.1 d911818dex101.htm EX-10.1 198517
4 EX-99.1 d911818dex991.htm EX-99.1 11662
5 EX-99.2 d911818dex992.htm EX-99.2 20364
9 GRAPHIC g911818oric.jpg GRAPHIC 8807
  Complete submission text file 0001193125-25-129531.txt   555373

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA oric-20250523.xsd EX-101.SCH 2860
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE oric-20250523_lab.xml EX-101.LAB 18738
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE oric-20250523_pre.xml EX-101.PRE 11714
19 EXTRACTED XBRL INSTANCE DOCUMENT d911818d8k_htm.xml XML 3779
Mailing Address 240 E. GRAND AVE. 2ND FLOOR SOUTH SAN FRANCISCO CA 94080
Business Address 240 E. GRAND AVE. 2ND FLOOR SOUTH SAN FRANCISCO CA 94080 (650) 388-5600
Oric Pharmaceuticals, Inc. (Filer) CIK: 0001796280 (see all company filings)

EIN.: 471787157 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39269 | Film No.: 25996005
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)